These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 33122847

  • 1. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
    Yang L, Zhou F, Zhuang Y, Liu Y, Xu L, Zhao H, Xiang Y, Dai X, Liu Z, Huang X, Wang L, Zhao C.
    Br J Cancer; 2021 Feb; 124(3):645-657. PubMed ID: 33122847
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of Jak-STAT3 pathway enhances bufalin-induced apoptosis in colon cancer SW620 cells.
    Zhu Z, Li E, Liu Y, Gao Y, Sun H, Ma G, Wang Z, Liu X, Wang Q, Qu X, Liu Y, Yu Y.
    World J Surg Oncol; 2012 Oct 30; 10():228. PubMed ID: 23110625
    [Abstract] [Full Text] [Related]

  • 3. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
    Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R.
    Eur J Med Chem; 2019 Nov 01; 181():111535. PubMed ID: 31376566
    [Abstract] [Full Text] [Related]

  • 4. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
    Zhu F, Dai C, Fu Y, Loo JF, Xia D, Gao SP, Ma Z, Chen Z.
    Oncotarget; 2016 Feb 23; 7(8):9462-76. PubMed ID: 26843613
    [Abstract] [Full Text] [Related]

  • 5. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X.
    Theranostics; 2021 Feb 23; 11(2):824-840. PubMed ID: 33391507
    [Abstract] [Full Text] [Related]

  • 6. Acetyl-macrocalin B, an ent-kaurane diterpenoid, initiates apoptosis through the ROS-p38-caspase 9-dependent pathway and induces G2/M phase arrest via the Chk1/2-Cdc25C-Cdc2/cyclin B axis in non-small cell lung cancer.
    Wang JN, Zhang ZR, Che Y, Yuan ZY, Lu ZL, Li Y, Li N, Wan J, Sun HD, Sun N, Puno PT, He J.
    Cancer Biol Ther; 2018 Jul 03; 19(7):609-621. PubMed ID: 29565730
    [Abstract] [Full Text] [Related]

  • 7. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY, Chao TT, Tai WT, Chang FY, Su WP, Chen YL, Chen PT, Weng CY, Yuan A, Shiau CW, Yu CJ, Chen KF.
    J Thorac Oncol; 2014 Apr 03; 9(4):488-96. PubMed ID: 24736071
    [Abstract] [Full Text] [Related]

  • 8. Bufalin inhibits the malignant development of non-small cell lung cancer by mediating the circ_0046264/miR-522-3p axis.
    Jin J, Yao Z, Qin H, Wang K, Xin X.
    Biotechnol Lett; 2021 Jun 03; 43(6):1229-1240. PubMed ID: 33534015
    [Abstract] [Full Text] [Related]

  • 9. Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells.
    Kim NY, Suh YA, Kim S, Lee C.
    Biosci Rep; 2020 Apr 30; 40(4):. PubMed ID: 32219334
    [Abstract] [Full Text] [Related]

  • 10. A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.
    Lee HJ, Min HY, Yong YS, Ann J, Nguyen CT, La MT, Hyun SY, Le HT, Kim H, Kwon H, Nam G, Park HJ, Lee J, Lee HY.
    Theranostics; 2022 Apr 30; 12(1):105-125. PubMed ID: 34987637
    [Abstract] [Full Text] [Related]

  • 11. HJC0152 suppresses human non-small-cell lung cancer by inhibiting STAT3 and modulating metabolism.
    Lu L, Li H, Wu X, Rao J, Zhou J, Fan S, Shen Q.
    Cell Prolif; 2020 Mar 30; 53(3):e12777. PubMed ID: 32022328
    [Abstract] [Full Text] [Related]

  • 12. Degradation of Mcl-1 through GSK-3β Activation Regulates Apoptosis Induced by Bufalin in Non-Small Cell Lung Cancer H1975 Cells.
    Kang XH, Zhang JH, Zhang QQ, Cui YH, Wang Y, Kou WZ, Miao ZH, Lu P, Wang LF, Xu ZY, Cao F.
    Cell Physiol Biochem; 2017 Mar 30; 41(5):2067-2076. PubMed ID: 28419994
    [Abstract] [Full Text] [Related]

  • 13. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
    Yan X, Li P, Zhan Y, Qi M, Liu J, An Z, Yang W, Xiao H, Wu H, Qi Y, Shao H.
    Biochem Pharmacol; 2018 Apr 30; 150():72-85. PubMed ID: 29360439
    [Abstract] [Full Text] [Related]

  • 14. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis.
    Zhang DM, Liu JS, Tang MK, Yiu A, Cao HH, Jiang L, Chan JY, Tian HY, Fung KP, Ye WC.
    Eur J Pharmacol; 2012 Oct 05; 692(1-3):19-28. PubMed ID: 22841670
    [Abstract] [Full Text] [Related]

  • 15. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
    Mitra P, Yang RM, Sutton J, Ramsay RG, Gonda TJ.
    Oncotarget; 2016 Feb 23; 7(8):9069-83. PubMed ID: 26812885
    [Abstract] [Full Text] [Related]

  • 16. Bufalin induces apoptosis in vitro and has Antitumor activity against human lung cancer xenografts in vivo.
    Wu SH, Bau DT, Hsiao YT, Lu KW, Hsia TC, Lien JC, Ko YC, Hsu WH, Yang ST, Huang YP, Chung JG.
    Environ Toxicol; 2017 Apr 23; 32(4):1305-1317. PubMed ID: 27444971
    [Abstract] [Full Text] [Related]

  • 17. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
    Hou T, Ray S, Brasier AR.
    J Biol Chem; 2007 Dec 21; 282(51):37091-102. PubMed ID: 17956865
    [Abstract] [Full Text] [Related]

  • 18. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
    Liu X, Xiao XY, Shou QY, Yan JF, Chen L, Fu HY, Wang JC.
    J Ethnopharmacol; 2016 Dec 04; 193():538-545. PubMed ID: 27686271
    [Abstract] [Full Text] [Related]

  • 19. Targeting CDK9 for treatment of colorectal cancer.
    Rahaman MH, Lam F, Zhong L, Teo T, Adams J, Yu M, Milne RW, Pepper C, Lokman NA, Ricciardelli C, Oehler MK, Wang S.
    Mol Oncol; 2019 Oct 04; 13(10):2178-2193. PubMed ID: 31398271
    [Abstract] [Full Text] [Related]

  • 20. MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity via Direct Binding to the STAT3 DNA-Binding Domain.
    Son DJ, Zheng J, Jung YY, Hwang CJ, Lee HP, Woo JR, Baek SY, Ham YW, Kang MW, Shong M, Kweon GR, Song MJ, Jung JK, Han SB, Kim BY, Yoon DY, Choi BY, Hong JT.
    Theranostics; 2017 Oct 04; 7(18):4632-4642. PubMed ID: 29158850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.